1 Result(s)

Article

CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) as gefitinib emerged as an accepted treatment in second- or third-line setting in NSCLC. However, clinical surrogate markers of EGFR-TKI...

F Barlési, C Tchouhadjian, C Doddoli, J-P Torre, P Astoul… in British Journal of Cancer (2005)